Beyond maximum grade: key regulatory considerations in adverse event reporting
Kyriaki Tzogani, Tarec C El-Galaly, Neil Everest, Christian Gisselbrecht et autres
0 citationsThe Lancet Haematology
Christian Gisselbrecht
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
420Publications signalées
36435Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCNS Lymphoma Diagnosis and TreatmentCAR-T cell therapy researchViral-associated cancers and disorders
Publications récentes
Large B-cell lymphoma: The LYSA pragmatic guidelines
Pierre Sesques, Guillaume Manson, Sydney Dubois, François‐Xavier Gros et autres
2 citationsEuropean Journal of Cancer
Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma
Franck Morschhauser, Hervé Ghesquières, Manali Kamdar, Fei‐Fei Liu et autres
1 citationHematological Oncology
Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa
David Sibon, Christian Gisselbrecht, Thierry Jo Molina, Vincent Camus et autres
7 citationsBlood
Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
Christian Gisselbrecht, David Sibon
1 citationBritish Journal of Haematology
Reaching beyond maximum grade:progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam, Lori M. Minasian, Vishal Bhatnagar, Franco Cavalli et autres
24 citationsWhite Rose Research Online (University of Leeds, The University of Sheffield, University of York)
From Stem Cell Transplantation to CAR-T Therapy in Relapse-Refractory Diffuse Large B-Cell Lymphoma
Christian Gisselbrecht, Eric W Van Den Neste
0 citationsMedical Research Archives
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis et autres
88 citationsBlood Advances
The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
Julio Delgado, Caroline Voltz, Milena Stain, Ewa Bałkowiec-Iskra et autres
10 citationsHemaSphere
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
Julio Delgado, Małgorzata Zienowicz, Paula B. van Hennik, Alexandre Moreau et autres
4 citationsThe Oncologist
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
Julio Delgado, Caroline Voltz, Milena Stain, Tuomo Lapveteläinen et autres
9 citationsHemaSphere
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
Julio Delgado, Filip Josephson, Jorge Camarero, Blanca Garcia-Ochoa et autres
13 citationsThe Oncologist
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.